{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:12:50Z","timestamp":1789441970146,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>Real-world evidence on fluoroquinolone-associated retinal detachment is contradictory. Therefore, we aim to examine the association between newly prescribed fluoroquinolones and the occurrence of retinal detachment with recent data from a large central European country.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A cohort study with an active comparator new user design was conducted. Dispensings of fluoroquinolone episodes were compared to a group of reference antibiotic episodes (amoxicillin, amoxicillin clavulanic acid, azithromycin, cefuroxime, cephalexin, clindamycin, sulfamethoxazole-trimethoprim, and doxycycline). Data from one of the largest statutory health insurances in Germany, the AOK, were used to follow up individuals with new antibiotic dispensing during the years 2014\u20132018 for the occurrence of retinal detachment. Piece-wise exponential additive mixed models adjusted for person-time, age, gender, comorbidities, year, and quarter at index were applied to estimate adjusted hazard ratios (aHR) with corresponding 95% confidence intervals (95% CI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In total, 15,232,585 antibiotic episodes were included in the cohort of which 0.05% episodes had an incident retinal detachment. The covariate-adjusted hazard ratio for fluoroquinolone episodes was 1.01 [0.95;1.08]. Likewise, in the propensity score-matched cohort the covariate-adjusted hazard ratio was 0.99 [0.92;1.07]. Moreover, there was little evidence for differences in age and gender subgroups, by follow-up time, selection of active comparator agent, dosage category, or censoring approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This large German cohort study found no meaningful real-world evidence for the association between fluoroquinolones and retinal detachment compared to a group of active comparator antibiotics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12886-025-04284-5","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T08:11:32Z","timestamp":1754554292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association between fluoroquinolones and retinal detachment: insights from a large German health claims-based cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Julia","family":"Wicherski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Peltner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Sch\u00fcssel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Br\u00fcckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schlotmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winfried V.","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Haenisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"4","key":"4284_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s40264-023-01286-4","volume":"46","author":"NF Ly","year":"2023","unstructured":"Ly NF, Flach C, Lysen TS, Markov E, van Ballegooijen H, Rijnbeek P, et al. Impact of European union label changes for Fluoroquinolone-Containing medicinal products for systemic and inhalation use: Post-Referral prescribing trends. Drug Saf. 2023;46(4):405\u201316.","journal-title":"Drug Saf"},{"key":"4284_CR2","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. European Medicines Agency. 2019. Report No.: EMA\/175398\/2019."},{"issue":"5","key":"4284_CR3","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1111\/aos.12931","volume":"94","author":"C Alves","year":"2016","unstructured":"Alves C, Penedones A, Mendes D, Batel Marques F. A systematic review and meta-analysis of the association between systemic fluoroquinolones and retinal detachment. Acta Ophthalmol. 2016;94(5):e251\u20139.","journal-title":"Acta Ophthalmol"},{"key":"4284_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejim.2020.01.009","volume":"75","author":"M Gatti","year":"2020","unstructured":"Gatti M, Bianchin M, Raschi E, De Ponti F. Assessing the association between fluoroquinolones and emerging adverse drug reactions Raised by regulatory agencies: an umbrella review. Eur J Intern Med. 2020;75:60\u201370.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"4284_CR5","doi-asserted-by":"crossref","first-page":"122","DOI":"10.32098\/mltj.03.2013.03","volume":"3","author":"A Menon","year":"2013","unstructured":"Menon A, Pettinari L, Martinelli C, Colombo G, Portinaro N, Dalle-Donne I, et al. New insights in extracellular matrix remodeling and collagen turnover related pathways in cultured human tenocytes after Ciprofloxacin administration. Muscles Ligaments Tendons J. 2013;3(3):122\u201331.","journal-title":"Muscles Ligaments Tendons J"},{"issue":"4","key":"4284_CR6","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/10715760902736275","volume":"43","author":"DA Lowes","year":"2009","unstructured":"Lowes DA, Wallace C, Murphy MP, Webster NR, Galley HF. The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells. Free Radic Res. 2009;43(4):323\u20138.","journal-title":"Free Radic Res"},{"issue":"1","key":"4284_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/jor.21196","volume":"29","author":"W-C Tsai","year":"2011","unstructured":"Tsai W-C, Hsu C-C, Chen CPC, Chang H-N, Wong AMK, Lin M-S, et al. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 2011;29(1):67\u201373.","journal-title":"J Orthop Res"},{"key":"4284_CR8","doi-asserted-by":"crossref","unstructured":"Ankamah E, Sebag J, Ng E, Nolan JM. Vitreous antioxidants, degeneration, and Vitreo-Retinopathy: exploring the links. Antioxid (Basel). 2019;9(1):7-27.","DOI":"10.3390\/antiox9010007"},{"issue":"9","key":"4284_CR9","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1167\/iovs.07-1456","volume":"49","author":"TL Ponsioen","year":"2008","unstructured":"Ponsioen TL, van Luyn MJ, van der Worp RJ, van Meurs JC, Hooymans JM, Los LI. Collagen distribution in the human vitreoretinal interface. Invest Ophthalmol Vis Sci. 2008;49(9):4089\u201395.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"4284_CR10","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1211\/0022357043932","volume":"56","author":"M Tanaka","year":"2004","unstructured":"Tanaka M, Takashina H, Tsutsumi S. Comparative assessment of ocular tissue distribution of drug-related radioactivity after chronic oral administration of 14\u00a0C-levofloxacin and 14\u00a0C-chloroquine in pigmented rats. J Pharm Pharmacol. 2004;56(8):977\u201383.","journal-title":"J Pharm Pharmacol"},{"key":"4284_CR11","unstructured":"Bundesministerium f\u00fcr Gesundheit (BMG). Gesetzliche Krankenversicherung - Mitglieder, mitversicherte Angeh\u00f6rige und Krankenstand 2024."},{"key":"4284_CR12","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (BfArM). Classifications 2024 [Available from: https:\/\/www.bfarm.de\/EN\/Code-systems\/Classifications\/_node.html"},{"issue":"6","key":"4284_CR13","doi-asserted-by":"publisher","first-page":"398","DOI":"10.7326\/M18-3079","volume":"170","author":"S Schneeweiss","year":"2019","unstructured":"Schneeweiss S, Rassen JA, Brown JS, Rothman KJ, Happe L, Arlett P, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398\u2013406.","journal-title":"Ann Intern Med"},{"key":"4284_CR14","unstructured":"Statistisches Bundesamt (DeStatis). Angaben zur Krankenversicherung (Ergebnisse des Mikrozensus)-Fachserie 13 Reihe 1.1\u20132019, 2020. Available from: https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Gesundheitszustand-Relevantes-Verhalten\/Publikationen\/Downloads-Gesundheitszustand\/krankenversicherung-mikrozensus-2130110199004.html"},{"key":"4284_CR15","unstructured":"Boyle P, Parkin DM. Statistical methods for registries. Cancer Registration: Principles and Methods 95. International Agency for Reseach on Cancer (IARC), World Health Organization (WHO): IARC Scientific Publication 1999. pp. 126\u2013\u200958."},{"issue":"3\u20134","key":"4284_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1471082X17748083","volume":"18","author":"A Bender","year":"2018","unstructured":"Bender A, Groll A, Scheipl F. A generalized additive model approach to time-to-event analysis. Stat Modelling. 2018;18(3\u20134):299\u2013321.","journal-title":"Stat Modelling"},{"issue":"13","key":"4284_CR17","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2012.383","volume":"307","author":"M Etminan","year":"2012","unstructured":"Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012;307(13):1414\u20139.","journal-title":"JAMA"},{"issue":"11","key":"4284_CR18","doi-asserted-by":"publisher","first-page":"e010077","DOI":"10.1136\/bmjopen-2015-010077","volume":"5","author":"N Daneman","year":"2015","unstructured":"Daneman N, Lu H, Redelmeier DA. Fluoroquinolones and collagen associated severe adverse events: a longitudinal cohort study. BMJ Open. 2015;5(11):e010077.","journal-title":"BMJ Open"},{"issue":"2","key":"4284_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/cid\/cit708","volume":"58","author":"SC Kuo","year":"2014","unstructured":"Kuo SC, Chen YT, Lee YT, Fan NW, Chen SJ, Li SY, et al. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis. 2014;58(2):197\u2013203.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4284_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40264-014-0138-y","volume":"37","author":"D Fife","year":"2014","unstructured":"Fife D, Zhu V, Voss E, Levy-Clarke G, Ryan P. Exposure to oral fluoroquinolones and the risk of retinal detachment: retrospective analyses of two large healthcare databases. Drug Saf. 2014;37(3):171\u201382.","journal-title":"Drug Saf"},{"issue":"6","key":"4284_CR21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ophtha.2013.12.006","volume":"121","author":"KG Kapoor","year":"2014","unstructured":"Kapoor KG, Hodge DO, St Sauver JL, Barkmeier AJ. Oral fluoroquinolones and the incidence of rhegmatogenous retinal detachment and symptomatic retinal breaks: a population-based study. Ophthalmology. 2014;121(6):1269\u201373.","journal-title":"Ophthalmology"},{"issue":"7","key":"4284_CR22","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/pds.3623","volume":"23","author":"K Eftekhari","year":"2014","unstructured":"Eftekhari K, Ghodasra DH, Haynes K, Chen J, Kempen JH, VanderBeek BL. Risk of retinal tear or detachment with oral fluoroquinolone use: a cohort study. Pharmacoepidemiol Drug Saf. 2014;23(7):745\u201352.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"20","key":"4284_CR23","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1001\/jama.2013.280500","volume":"310","author":"B Pasternak","year":"2013","unstructured":"Pasternak B, Svanstr\u00f6m H, Melbye M, Hviid A. Association between oral fluoroquinolone use and retinal detachment. JAMA. 2013;310(20):2184\u201390.","journal-title":"JAMA"},{"issue":"6","key":"4284_CR24","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s00228-021-03260-4","volume":"78","author":"MK Taher","year":"2022","unstructured":"Taher MK, Crispo JAG, Fortin Y, Moog R, McNair D, Bjerre LM, et al. Systemic quinolones and risk of retinal detachment III: a nested case\u2013control study using a US electronic health records database. Eur J Clin Pharmacol. 2022;78(6):1019\u201328.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4284_CR25","doi-asserted-by":"publisher","first-page":"e0195563","DOI":"10.1371\/journal.pone.0195563","volume":"13","author":"SY Choi","year":"2018","unstructured":"Choi SY, Lim HA, Yim HW, Park YH. Administration of oral fluoroquinolone and the risk of rhegmatogenous retinal detachment: A nationwide population-based study in Korea. PLoS ONE. 2018;13(4):e0195563.","journal-title":"PLoS ONE"},{"issue":"9","key":"4284_CR26","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/jac\/dku145","volume":"69","author":"CS Chui","year":"2014","unstructured":"Chui CS, Man KK, Cheng CL, Chan EW, Lau WC, Cheng VC, et al. An investigation of the potential association between retinal detachment and oral fluoroquinolones: a self-controlled case series study. J Antimicrob Chemother. 2014;69(9):2563\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"4284_CR27","doi-asserted-by":"publisher","first-page":"e0275796","DOI":"10.1371\/journal.pone.0275796","volume":"17","author":"AA Londhe","year":"2022","unstructured":"Londhe AA, Holy CE, Weaver J, Fonseca S, Villasis-Keever A, Fife D. Risk of retinal detachment and exposure to fluoroquinolones, common antibiotics, and febrile illness using a self-controlled case series study design: retrospective analyses of three large healthcare databases in the US. PLoS ONE. 2022;17(10):e0275796.","journal-title":"PLoS ONE"},{"issue":"7","key":"4284_CR28","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1001\/jamaophthalmol.2024.1712","volume":"142","author":"JP Brown","year":"2024","unstructured":"Brown JP, Wing K, Evans SJ, Leyrat C, Mansfield KE, Smeeth L, et al. Systemic fluoroquinolone use and risk of uveitis or retinal detachment. JAMA Ophthalmol. 2024;142(7):636\u201345.","journal-title":"JAMA Ophthalmol"},{"key":"4284_CR29","first-page":"13","volume":"4","author":"V Strassmann","year":"2012","unstructured":"Strassmann V, Gr\u00fcger T. Fluorchinolone und Das Potenzielle Risiko einer Netzhautabl\u00f6sung. Bull Zur Arzneimittelsicherheit - Informationen Aus BfArM Und PEI. 2012;4:13\u20139.","journal-title":"Bull Zur Arzneimittelsicherheit - Informationen Aus BfArM Und PEI"},{"issue":"1","key":"4284_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12916-025-03919-0","volume":"23","author":"J Wicherski","year":"2025","unstructured":"Wicherski J, Peltner J, Becker C, Sch\u00fcssel K, Br\u00fcckner G, Schlotmann A, et al. High risk for life-threatening adverse events of fluoroquinolones in young adults: a large German population-based cohort study. BMC Med. 2025;23(1):76.","journal-title":"BMC Med"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04284-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04284-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T22:31:21Z","timestamp":1757370681000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-025-04284-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4284"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04284-5","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"25 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.\u00a0All authors declare no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable. Data access was legally approved by the Scientific Research Institute of the AOK (WIdO). The study is based on anonymised administrative claims data that never involved patients directly. Individual patients cannot be identified and the analyses presented do not affect patients whose anonymized records were used. No ethical approval or consent to participate needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}}],"article-number":"447"}}